首页> 美国卫生研究院文献>PLoS Computational Biology >Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2 SLC1A5) from Homology Modeling and Virtual Screening
【2h】

Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2 SLC1A5) from Homology Modeling and Virtual Screening

机译:从同源性建模和虚拟筛选中发现丙氨酸-丝氨酸-半胱氨酸转运蛋白(ASCT2SLC1A5)的配体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Alanine-Serine-Cysteine transporter ASCT2 (SLC1A5) is a membrane protein that transports neutral amino acids into cells in exchange for outward movement of intracellular amino acids. ASCT2 is highly expressed in peripheral tissues such as the lung and intestines where it contributes to the homeostasis of intracellular concentrations of neutral amino acids. ASCT2 also plays an important role in the development of a variety of cancers such as melanoma by transporting amino acid nutrients such as glutamine into the proliferating tumors. Therefore, ASCT2 is a key drug target with potentially great pharmacological importance. Here, we identify seven ASCT2 ligands by computational modeling and experimental testing. In particular, we construct homology models based on crystallographic structures of the aspartate transporter GltPh in two different conformations. Optimization of the models’ binding sites for protein-ligand complementarity reveals new putative pockets that can be targeted via structure-based drug design. Virtual screening of drugs, metabolites, fragments-like, and lead-like molecules from the ZINC database, followed by experimental testing of 14 top hits with functional measurements using electrophysiological methods reveals seven ligands, including five activators and two inhibitors. For example, aminooxetane-3-carboxylate is a more efficient activator than any other known ASCT2 natural or unnatural substrate. Furthermore, two of the hits inhibited ASCT2 mediated glutamine uptake and proliferation of a melanoma cancer cell line. Our results improve our understanding of how substrate specificity is determined in amino acid transporters, as well as provide novel scaffolds for developing chemical tools targeting ASCT2, an emerging therapeutic target for cancer and neurological disorders.
机译:丙氨酸-丝氨酸-半胱氨酸转运蛋白ASCT2(SLC1A5)是一种膜蛋白,可将中性氨基酸转运到细胞中,以交换细胞内氨基酸的向外移动。 ASCT2在周围组织(如肺和肠)中高度表达,在其中有助于中性氨基酸的细胞内浓度的体内平衡。通过将氨基酸营养物质(例如谷氨酰胺)转运到增生的肿瘤中,ASCT2在多种癌症(例如黑色素瘤)的发展中也起着重要作用。因此,ASCT2是具有潜在重要药理学重要性的关键药物靶标。在这里,我们通过计算模型和实验测试确定了七个ASCT2配体。特别是,我们基于两种不同构型的天冬氨酸转运蛋白GltPh的晶体结构构建同源性模型。对蛋白质-配体互补性的模型结合位点的优化揭示了可以通过基于结构的药物设计来靶向的新推定口袋。从ZINC数据库中对药物,代谢物,片段样和铅样分子进行虚拟筛选,然后使用电生理学方法对功能强大的14种热门药物进行实验测试,结果发现了7种配体,其中包括5种激活剂和2种抑制剂。例如,氨基氧杂环丁烷-3-羧酸盐是比任何其他已知的ASCT2天然或非天然底物更有效的活化剂。此外,两个命中抑制了ASCT2介导的谷氨酰胺摄取和黑色素瘤癌细胞系的增殖。我们的结果增进了我们对如何确定氨基酸转运蛋白中底物特异性的理解,并为开发靶向ASCT2的化学工具提供了新颖的支架,ASCT2是癌症和神经系统疾病的新兴治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号